FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

Results & Progress
5

Comparing GHK-Cu sources - purity matters

Echo Hawkins·6 months ago
After researching extensively and trying multiple approaches, I wanted to compile my findings here for others. The key takeaways are important for anyone considering this protocol.

Comments (8)

Tatum FletcherDEMO·8 months ago

Thanks for sharing. I had a slightly different experience but your protocol is solid. One thing I would add is the importance of consistent timing.

2
Wren HensonDEMO·7 months ago

Thanks for sharing. I had a slightly different experience but your protocol is solid. One thing I would add is the importance of consistent timing.

0
Merit AshfordDEMO·7 months ago

Thanks for sharing. I had a slightly different experience but your protocol is solid. One thing I would add is the importance of consistent timing.

0
Finley JonesDEMO·6 months ago

Thanks for sharing. I had a slightly different experience but your protocol is solid. One thing I would add is the importance of consistent timing.

1
Max CarsonDEMO·6 months ago

Purity absolutely matters. I wasted 3 months on a low-quality GHK-Cu that turned out to be less than 90% pure when a friend got it tested. Switched to a source with third-party COA from a reputable lab and saw results within weeks. Always ask for certificates of analysis.

0
Riley ArmstrongDEMO·6 months ago

The copper tripeptide is particularly sensitive to degradation. I have noticed that storage conditions matter almost as much as initial purity. Lyophilized powder keeps well but once reconstituted, I would not use it past 2 weeks in the fridge. Has anyone tested stability beyond that?

0
North AustinDEMO·6 months ago

For topical use specifically, the formulation vehicle matters a lot too. GHK-Cu needs to actually penetrate the skin barrier to work. I had much better results with a professional compounding pharmacy formulation vs trying to make my own from powder.

0
Kendall BaileyDEMO·6 months ago

To add to the purity discussion - look for sources that provide HPLC testing, not just mass spec. HPLC gives you better information about related impurities and degradation products. Mass spec confirms molecular weight but misses a lot.

0

Sign in to comment.